Cerus Invites You to a Company Update via the Web.Business Editors and Health/Medical Writers CONCORD, Calif.--(BW HealthWire)--June 4, 2002 You are invited to listen to a conference call that will be broadcast live over the Internet on June 4, 2002 at 10:00 a.m. ET with Stephen Isaacs, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Greg Schafer, CFO See Chief Financial Officer. , Laurence Corash, M.D., VP, Medical Affairs and Jim Vaughn, R.Ph., VP Marketing of Cerus Corporation. What: Discuss news released earlier today concerning European Approval of the INTERCEPT Platelet System Disposable Set. When: Tuesday, June 4, 2002 at 10:00 a.m. Eastern Time Where: http://www.videonewswire.com/event.asp?id=5764 How: Live over the Internet -- Simply log on to the web at the address above Contact: Lisa Luttinger/Cerus Corporation, 925/288-6036 Cerus Corporation is building on its leading position in the biopharmaceutical industry by developing medical systems and therapeutics to provide safer and more effective options to patients. The company is developing products based on its proprietary Helinx(R) technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the world's blood supply. These INTERCEPT Blood Systems, based on the company's Helinx technology, are designed to inactivate in·ac·ti·vate v. 1. To render nonfunctional. 2. To make quiescent. in·ac  ti·va viruses,
bacteria, other pathogens and white blood cells White blood cellsA group of several cell types that occur in the bloodstream and are essential for a properly functioning immune system. Mentioned in: Abscess Incision & Drainage, Bone Marrow Transplantation, Complement Deficiencies . In collaboration with its partner, Baxter Healthcare Corporation, the company has submitted a CE Mark application seeking European approval for the INTERCEPT Platelet System, and has begun the regulatory submission process in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The companies are preparing to begin the U.S. regulatory submission process for the INTERCEPT Plasma system, which will be followed by a CE Mark application for this product. The INTERCEPT Red Blood Cell red blood cell: see blood. System is in Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the stage. The Concord, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases. If you are unable to participate during the live webcast, the call will be archived for 72 hours on the Website www.cerus.com. (Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from www.real.com/products/player/index.html, and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to webmaster@vdat.com.) Note to Editors: Helinx is a trademark of Cerus Corporation Intercept is a trademark of Baxter International Baxter International Inc. (NYSE: BAX), is a global healthcare company with 48,000 employees and 2006 sales of US$10.4 billion. Its headquarters is in Deerfield, Illinois. , Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion